Neuphoria Therapeutics Inc/$NEUP
13:30
14:25
15:15
16:10
17:00
1D1W1MYTD1Y5YMAX
About Neuphoria Therapeutics Inc
Neuphoria Therapeutics Inc is a clinical stage biotechnology company dedicated to developing therapies that address the complex needs of individuals affected by neuropsychiatric disorders. The company is advancing its drug candidate, BNC 210, an oral, proprietary, selective negative allosteric modulator of the Alpha7 nicotinic acetylcholine receptor, for the acute treatment of social anxiety disorder and for chronic treatment of post-traumatic stress disorder.
Ticker
$NEUP
Sector
Primary listing
Industry
Biotechnology
Headquarters
Employees
-
ISIN
US64136E1029
Website
NEUP Metrics
BasicAdvanced
$13M
4196.59
$0.00
-
-
Price and volume
Market cap
$13M
52-week high
$7.67
52-week low
$4.33
Average daily volume
32K
Financial strength
Current ratio
11.011
Quick ratio
10.998
Long term debt to equity
0.074
Total debt to equity
0.663
Profitability
EBITDA (TTM)
-0.025
Gross margin (TTM)
106.82%
Net profit margin (TTM)
37.20%
Operating margin (TTM)
-3.01%
Effective tax rate (TTM)
-4.22%
Management effectiveness
Return on equity (TTM)
25.45%
Valuation
Price to earnings (TTM)
4,196.586
Price to revenue (TTM)
818.599
Price to book
0.51
Price to tangible book (TTM)
1.05
Price to free cash flow (TTM)
19,696.133
Free cash flow yield (TTM)
0.01%
Free cash flow per share (TTM)
0.04%
Growth
Revenue change (TTM)
-35,282.09%
Earnings per share change (TTM)
-103.74%
3-year revenue growth (CAGR)
97.22%
10-year revenue growth (CAGR)
1.26%
3-year earnings per share growth (CAGR)
-46.41%
10-year earnings per share growth (CAGR)
-15.72%
NEUP News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Neuphoria Therapeutics Inc stock?
Neuphoria Therapeutics Inc (NEUP) has a market cap of $13M as of July 04, 2025.
What is the P/E ratio for Neuphoria Therapeutics Inc stock?
The price to earnings (P/E) ratio for Neuphoria Therapeutics Inc (NEUP) stock is 4196.59 as of July 04, 2025.
Does Neuphoria Therapeutics Inc stock pay dividends?
No, Neuphoria Therapeutics Inc (NEUP) stock does not pay dividends to its shareholders as of July 04, 2025.
When is the next Neuphoria Therapeutics Inc dividend payment date?
Neuphoria Therapeutics Inc (NEUP) stock does not pay dividends to its shareholders.
What is the beta indicator for Neuphoria Therapeutics Inc?
Neuphoria Therapeutics Inc (NEUP) does not currently have a Beta indicator.